Key opinion leaders provide their final thoughts on treatment management for patients with MDS. Ryan Haumschild, PharmD, MS, MBA: Thank you for this rich and informative discussion. Before we conclude ...
Ryan Haumschild, PharmD, MS, MBA: Dr Zeidan, what are your thoughts on clinical pathways? Because clinical pathways are getting used more and more. Dr Weaver brought that up. But for a unique patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback